.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR03_TenofovirDisoproxilAndEm.TenofovirDisoproxilAndEm .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR03_TenofovirDisoproxilAndEm.TenofovirDisoproxilAndEm| name: | TenofovirDisoproxilAndEmtricitabine |
| ATC code: | J05AR03 | route: | oral |
| n-compartments | 1 |
Tenofovir disoproxil and emtricitabine is a fixed-dose combination antiretroviral medication used for the treatment and prevention (pre-exposure prophylaxis, PrEP) of HIV-1 infection in adults and adolescents. Both drugs are reverse transcriptase inhibitors: tenofovir is a nucleotide analog, and emtricitabine is a nucleoside analog. The combination is currently approved and widely used in clinical practice.
Pharmacokinetics reported in healthy adult volunteers, steady-state, after oral administration under fasting conditions.
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703
Ogbuagu, O (2016). Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert review of anti-infective therapy 14(12) 1113–1126. DOI:10.1080/14787210.2016.1255551 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27797606
Scott, RK, et al., & Bies, R (2023). Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy. Frontiers in reproductive health 5 1224580–None. DOI:10.3389/frph.2023.1224580 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37830105